PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Pirogov Russian National Research Medical University, Moscow, Russia.\', \'City Clinical Hospital No. 52, Moscow, Russia.\', \'Volgograd State Medical University, Volgograd, Russia.\', \'Azerbaijan State Medical University, Baku, Azerbaijan.\', \'Moscow State University of Food Production, Moscow, Russia.\', \'South Ural State Medical University, Chelyabinsk, Russia.\', \'Altai State Medical University, Barnaul, Russia.\', \'Pitirim Sorokin Syktyvkar State University, Syktyvkar, Russia.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.17116/jnevro202212201184
?:doi
?:hasPublicationType
?:journal
  • Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
is ?:pmid of
?:pmid
?:pmid
  • 35175707
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.135
?:rankingScore_hIndex
  • 12
is ?:relation_isRelatedTo_publication of
?:title
  • [Determination of the prevalence of postcovid syndrome and assessment of the effectiveness of the drug Cortexin in the treatment of neurological disorders in patients with postcovid syndrome. Results of the multicenter clinical and epidemiological observational program CORTEX].
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all